Nexalin Technology, Inc. (NXL)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Medical Products	301.65K	168.72K	110.75K	1.32M	144.07K
Medical Products Growth	78.78%	52.35%	-91.62%	817.20%	-40.69%
Total	301.65K	168.72K	110.75K	1.32M	144.07K
Total Growth	78.78%	52.35%	-91.62%	817.20%	-40.69%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
United States	111.35K	83.47K	107.13K	113.54K	117.93K
United States Growth	33.39%	-22.09%	-5.64%	-3.72%	-51.45%
China	190.30K	85.25K	3.61K	1.21M	26.13K
China Growth	123.23%	2258.83%	-99.70%	4521.98%	-
Total	301.65K	168.72K	110.75K	1.32M	144.07K
Total Growth	78.78%	52.35%	-91.62%	817.20%	-40.69%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 6, 2026

Data Sources Report a data error